Evidence map›Paper›PMID 31286233›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.

Joanne M Bowen, Rachel J Gibson, Janet K Coller, Nicole Blijlevens, Paolo Bossi, Noor Al-Dasooqi, Emma H Bateman, Karen Chiang, Charlotte de Mooij, Bronwen Mayo and 11 more

Open access · greenAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 4 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  3. Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Reporting quality and spin in abstracts of randomized clinical trials related to oral mucositis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 5 countries.

Joanne M Bowen *Adelaide Medical School, University of Adelaide, Adelaide, Australia. joanne.bowen@adelaide.edu.au.ORCID http://orcid.org/0000-0003-0876-0031
Rachel J Gibson *Division of Health Sciences, University of South Australia, Adelaide, Australia.
Janet K CollerAdelaide Medical School, University of Adelaide, Adelaide, Australia.
Nicole BlijlevensRadboud University Medical Centre, Nijmegen, The Netherlands.
Paolo BossiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health - Medical Oncology, University of Brescia, Brescia, Italy.
Noor Al-DasooqiAdelaide Medical School, University of Adelaide, Adelaide, Australia.
Emma H BatemanAdelaide Medical School, University of Adelaide, Adelaide, Australia.
Karen ChiangSt Vincent's Hospital, Melbourne, Australia.
Charlotte de MooijRadboud University Medical Centre, Nijmegen, The Netherlands.
Bronwen MayoDivision of Health Sciences, University of South Australia, Adelaide, Australia.
Andrea M StringerDivision of Health Sciences, University of South Australia, Adelaide, Australia.
Wim TissingUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Hannah R WardillAdelaide Medical School, University of Adelaide, Adelaide, Australia.
Ysabella Z A van SebilleDivision of Health Sciences, University of South Australia, Adelaide, Australia.
Vinisha RannaDepartment of Oral and Maxillofacial Surgery, The Mount Sinai Hospital, New York, NY, USA.
Anusha VaddiOral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA.
Dorothy Mk KeefeAdelaide Medical School, University of Adelaide, Adelaide, Australia.
Rajesh V LallaSection of Oral Medicine, University of Connecticut Health, Farmington, CT, USA.
Karis Kin Fong ChengAlice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Sharon EladOral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA.
Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
The University of Adelaide · AUUniversity of South Australia · AURadboud University Nijmegen · NLUniversity of Rochester Medical Center · USMount Sinai Hospital · USNational University of Singapore · SGSt Vincent's Hospital Melbourne · AUUConn Health · USUniversity Medical Center Groningen · NLUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to update the clinical practice guidelines for the use of agents for the prevention and/or treatment of gastrointestinal mucositis (GIM).

methodsA systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, and No Guideline Possible.

resultsA total of 78 papers across 13 interventions were examined of which 25 were included in the final review. No new guidelines were possible for any agent due to inadequate and/or conflicting evidence. Existing guidelines for probiotics and hyperbaric oxygen were unchanged.

conclusionsOf the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM.

Indexed as

Practice Guidelines as TopicButyric AcidChemoradiotherapyFibroblast Growth Factor 7GlutamineHumansHyperbaric OxygenationMucositisNeoplasmsProctitisStomatitisButyric AcidFibroblast Growth Factor 7GlutamineClinical managementGastrointestinalGuidelinesMucositis

Identifiers

PMID31286233
OpenAlexW2957310090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.